Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

PrOD ± ribavirin highly effective in HCV patients with advanced hepatic fibrosis, compensated cirrhosis

18 May 2019
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

Use of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin is very effective in the treatment of chronic hepatitis C with advanced hepatic fibrosis or compensated cirrhosis, according to a recent study, adding that Child-Pugh A6 must be an exclusion criterion for first-line treatment in these patients.

Of the 898 patients, 887 (98.8 percent) achieved sustained virologic response 12 weeks off therapy (SVR12) based on the per-protocol analysis (patients receiving ≥1 dose of any study medication and hepatitis C virus (HCV) RNA data available at post-treatment week 12). The only significant factor of poor SVR12 was Child-Pugh A6 (odds ratio [OR], 0.168; 95 percent CI, 0.043–0.659; p=0.011).

Fifty-four (5.7 percent) patients discontinued treatment due to hepatic decompensation (n=18; 1.9 percent) and other adverse reactions. In multivariate analyses, old age (OR, 1.062; 1.008–1.119; p=0.024) and Child-Pugh A6 (OR, 4.957; 1.691–14.528; p=0.004) significantly correlated with hepatic decompensation.

The authors enrolled 941 patients treated in four hospitals (the Keelung, the Linkuo, the Chiayi and the Kaohsiung Chang Gung Memorial Hospital) through a nationwide government-funded programme in Taiwan. Patients with HCV and advanced hepatic fibrosis or compensated cirrhosis received 12 weeks of PrOD for HCV-1b and 12 or 24 weeks of PrOD plus ribavirin therapy for HCV-1a without or with cirrhosis.

Ultrasonography, fibrosis index based on 4 factors (FIB-4) test, or transient elastography/acoustic radiation force impulse (ARFI) was used to confirm the advanced hepatic fibrosis or compensated cirrhosis in patients. Safety and efficacy of PrOD were evaluated.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.